Form 4: Mineralys Therapeutics Insider Trades Common Stock

David Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan.

Summary

• David Rodman, Chief Medical Officer at Mineralys Therapeutics, Inc. (MLYS), engaged in stock transactions on July 9, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on October 6, 2025.
• Rodman acquired 2,171 shares of common stock at a price of $16 per share.
• Concurrently, Rodman disposed of 2,171 shares of common stock at a price of $30.30 per share.
• Following these transactions, Rodman beneficially owns 57,733 shares of common stock.
• Additionally, a stock option for 2,171 shares, with an exercise price of $16 and an expiration date of February 9, 2033, is held by Rodman.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine insider transactions executed under a pre-established plan, without indicating significant positive or negative developments for the company.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially less market-sensitive trading activity.
• The acquisition of shares at a lower price ($16) and disposition at a higher price ($30.30) suggests a profitable trade for the executive.
• The continued beneficial ownership of a significant number of shares (57,733) indicates ongoing commitment to the company.

Negatives

• The disposition of 2,171 shares, even under a plan, represents a reduction in the executive's direct holdings.

Risks

• The filing does not explicitly mention any new or evolving risks.
• The primary risk associated with insider trading, even under a 10b5-1 plan, is the perception of executives selling shares, which could be misinterpreted by the market.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future company performance. It solely reports past transactions.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
• The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Mineralys Therapeutics' Chief Medical Officer is a common practice to facilitate planned stock sales or purchases by executives while mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders: The disposition of shares by an executive may be perceived negatively, although the use of a 10b5-1 plan mitigates this concern. The continued significant ownership suggests ongoing commitment.
• Employees: The stock option details indicate a standard employee incentive program.
• Management: The transaction reflects standard executive compensation and investment practices.

Next Steps

• Continued monitoring of insider transactions for any significant changes in beneficial ownership.
• Further vesting of the reported stock option over the next 36 months.

Key Dates

Keywords

SEC Form 4, Insider Trading, Mineralys Therapeutics, MLYS, Stock Transaction, Rule 10b5-1, Beneficial Ownership, Chief Medical Officer, Stock Option